After many blockbuster medications in psychiatry, there has been a relative lull of innovation.
Johnson & Johnson's Esketamine could be the first medication in an emerging new class for depression.
If approved, Esketamine could significantly improve revenue from J&J's Neuroscience division.
READ FULL ARTICLE HERE
Check, a first-of-its-kind payroll infrastructure startup whose mission is to make paying people simple, announced its public launch today with $35 million in Series B funding from Stripe and Thrive Capital.
MG+M The Law Firm (MG+M) is pleased to announce that it has elevated New York attorney Karina E. Murski
Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that Matthew S. Rheingold has been elevated from
Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that partners Thomas J. Snyder and Matheu D. Nunn
For partnerships, content marketing or advertising inquiries, please contact Edwin through his LinkedIn Profile
Connect© Copyright 2024 citybuzz
